Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Context Therapeutics Q3 2026 Results: Net Loss of $7.62M, Loss Narrows

Context Therapeutics Inc. is a clinical-stage biopharmaceutical company focusing on the development of CTIM-76 and CT-202, while winding down its CT-95 Phase 1 clinical trial. As of November 6, 2026, the company had 91,879,177 shares of common stock outstanding and is classified as a smaller reporting company and emerging growth company.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Net income-7.6-9.7
EPS (diluted, $ a share)$-0.08$-0.10

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Source

10-Q filed with the SEC, NASDAQ: CNTX. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Context Therapeutics Inc.: key numbers

Share price
$0.1659Close, Nov 16
Market cap
$15.2M
Shares outstanding
91.88MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Context Therapeutics Inc.

All →
4:24 PM ET 8-K
Financial Results

Context Therapeutics Financial Results

Context Therapeutics reported Q3 2026 financial results and provided a clinical update on its CTIM-76 program, which showed a 22% confirmed ORR and 5.6 months median PFS in platinum-resistant ovarian cancer. The company ended the quarter with $34.4 million in cash, providing a runway into Q4 2027.

Term
Q3 2026

“CTIM-76 continues to show promising activity in patients with PROC who had received a median of six prior lines of therapy. Our Phase 1b strategy is to evaluate CTIM-76 in patients with no more than five prior lines of therapy. These less heavily pretreated patients generally have lower tumor burden and better T cell fitness, providing a rationale to evaluate whether treatment in this population, together with Q3W dosing, can deliver greater clinical benefit and improved tolerability.”

Martin Lehr, Chief Executive Officer

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.